Showing 5 posts of 5 posts found.

Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms

June 28, 2023
Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause

Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …


FDA approves new nonhormonal medication for menopause hot flashes

May 15, 2023
Medical Communications FDA, HRT, Veozah, hot flashes, menopause

The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an oral medication to treat moderate …


Bayer scoops up women’s healthcare biotech KaNDy Therapeutics in potential $1bn+ deal

August 11, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, KaNDy Therapeutics, menopause, pharma

Bayer is set to acquire UK-based biotech KaNDy Therapeutics, assimilating the firm’s women’s healthcare development portfolio in a newly announced …

Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer

December 12, 2019
Business Services Journal of Medicine, Novartis, menopause

Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …


Astellas lines up Ogeda for acquisition in $853 million deal

April 3, 2017
Sales and Marketing Astellas, Ogeda SA, menopause

Astellas, based in Tokyo, has announced that it has agreed a deal to acquire Belgium-based Ogeda SA. The deal will …

Latest content